Clinical remission · people with active UC
Probiotics showed no clear difference in clinical remission compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (low certainty).
1 finding from 1 review
Serious adverse events · people with active UC
It is very uncertain whether probiotics changes serious adverse events compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with active UC
It is very uncertain whether probiotics changes withdrawal due to adverse events compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
It is very uncertain whether probiotics changes withdrawal due to adverse events (52 weeks) compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
1 finding from 1 review
Need for extra treatment · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life (52 weeks) · Patients with quiescent ulcerative colitis
1 finding from 1 review
Clinical relapse · Patients with quiescent ulcerative colitis
Probiotics showed no clear difference in clinical relapse (52 weeks) compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (low certainty).
1 finding from 1 review
Maintenance of clinical remission · Patients with quiescent ulcerative colitis
Probiotics showed no clear difference in maintenance of clinical remission (52 weeks) compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (low certainty).
1 finding from 1 review
Serious adverse events (52 weeks) · Patients with quiescent ulcerative colitis
It is very uncertain whether probiotics changes serious adverse events (52 weeks) compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
1 finding from 1 review
Adverse events mild adverse events · children aged over eight and adults with cystic fibrosis and chronic pulmonary infection with P aeruginosa
1 finding from 1 review
Need for antibiotics days of antibiotic use · children aged over eight and adults with cystic fibrosis and chronic pulmonary infection with P aeruginosa
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
QoL · children aged over eight and adults with cystic fibrosis and chronic pulmonary infection with P aeruginosa
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Sputum microbiology · children aged over eight and adults with cystic fibrosis and chronic pulmonary infection with P aeruginosa
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Inflammatory markers · children aged over eight and adults with cystic fibrosis and chronic pulmonary infection with P aeruginosa
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pulmonary exacerbations · children aged over eight and adults with cystic fibrosis and chronic pulmonary infection with P aeruginosa
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
FEV1 (% predicted): mean change from baseline · children aged over eight and adults with cystic fibrosis and chronic pulmonary infection with P aeruginosa
Summary of findings: garlic supplementation showed no clear difference in respiratory function change from baseline in % predicted FEV1 compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
FEV1 change from start of treatment (L) · adults and children with cystic fibrosis and P aeruginosa
1 finding from 1 review
Intervention not reported
FEV1 change from start of treatment (% predicted) · adults and children with cystic fibrosis and P aeruginosa
1 finding from 1 review
Intervention not reported
Time to next exacerbation · adults and children with cystic fibrosis and P aeruginosa
1 finding from 1 review
Intervention not reported
Adverse events: number of moderate adverse events · adults and children with cystic fibrosis and P aeruginosa
The intervention showed no clear difference in adverse events: number of moderate adverse events (moderate certainty).
1 finding from 1 review